UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): October 12, 2021
AUGMEDIX, INC.
(Exact name of registrant as specified in its charter)
| Delaware | | 000-56036 | | 83-3299164 |
| (State or other jurisdiction of incorporation) | | (Commission File Number) | | (I.R.S. Employer Identification No.) |
| 111 Sutter Street, Suite 1300 | | |
| San Francisco, California | | 94104 |
| (Address of principal executive offices) | | (Zip Code) |
Registrant’s telephone number, including area code: (888) 649-4885
None
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | | Trading Symbol(s) | | Name of each exchange on which
registered |
| | | | |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 1.01. Entry into a Material Definitive Agreement.
On October 12, 2021, Augmedix Operating Corp. f/k/a Augmedix, Inc., a Delaware corporation (the “Company”), entered into an Addendum to Statement of Work No. 3 (the “Addendum”) with IDS Infotech Limited (the “Service Provider”), which amends and supplements the Statement of Work No. 3 (the “SOW No. 3”), entered into on August 10, 2021, between the Company and the Service Provider. The Addendum, among other things, adds Augmedix Notes, the non-real time medical documentation solution provided by the Company (the “Augmedix Notes”), to the SOW No. 3 for a pilot period beginning on the effective date of the SOW No. 3 and expiring three (3) months following the first day the Service Provider begins producing one or more charts for all or part of an Augmedix Note user’s scheduled shift.
The Addendum is furnished as Exhibit 10.1 to this current report on Form 8-K and is incorporated herein by reference. The foregoing description of the Addendum does not purport to be complete and is qualified in its entirety by reference to the Addendum.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
| * | Portions of this exhibit (indicated by asterisks) have been omitted in accordance with the rules of the SEC. |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | AUGMEDIX, INC. |
| | |
| | By: | /s/ PAUL GINOCCHIO |
| | | Name: | Paul Ginocchio |
| | | Title: | Chief Financial Officer |
| | | | |
| Date: October 15, 2021 | | | |
2
